Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Confocal fluorescence microscopy: An ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells.

  2015cited by this paper
• Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure Duration as Well as Triple-Drug Combination Levels in Cells Within Lymph Nodes and Blood in Primates

  2015cited by this paper
• Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission

  2015cited by this paper
• Serial Cervicovaginal Exposures With Replication-Deficient SIVsm Induce Higher Dendritic Cell (pDC) and CD4+ T-Cell Infiltrates Not Associated With Prevention but a More Severe SIVmac251 Infection of Rhesus Macaques

  2014cited by this paper
• Overview of nano-drugs characteristics for clinical application: the journey from the entry to the exit point

  2014cited by this paper
• HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention

  2014cited by this paper
• Humanized-BLT mouse model of Kaposi’s sarcoma-associated herpesvirus infection

  2014cited by this paper
• Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus

  2014cited by this paper
• A Compartmental Pharmacokinetic Evaluation of Long‐Acting Rilpivirine in HIV‐Negative Volunteers for Pre‐Exposure Prophylaxis

  2014cited by this paper
• HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.

  2014cited by this paper
• Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention.

  2014cited by this paper
• Long-acting injectable antiretrovirals for HIV treatment and prevention

  2013cited by this paper
• Antiretroviral preexposure prophylaxis for HIV prevention.

  2013cited by this paper
• Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for HIV Type 1 Treatment

  2013cited by this paper
• Next-generation oral preexposure prophylaxis: beyond tenofovir

  2012cited by this paper
• Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.

  2012cited by this paper
• Safety and Pharmacokinetics of Intravaginal Rings Delivering Tenofovir in Pig-Tailed Macaques

  2012cited by this paper
• Preexposure prophylaxis for HIV infection among African women.

  2012cited by this paper
• Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.

  2012cited by this paper
• Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection

  2012cited by this paper
• Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.

  2012cited by this paper
• Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence

  2012cited by this paper
• Durable Protection from Vaginal Simian-Human Immunodeficiency Virus Infection in Macaques by Tenofovir Gel and Its Relationship to Drug Levels in Tissue

  2011cited by this paper
• One Percent Tenofovir Applied Topically to Humanized BLT Mice and Used According to the CAPRISA 004 Experimental Design Demonstrates Partial Protection from Vaginal HIV Infection, Validating the BLT Model for Evaluation of New Microbicide Candidates

  2011cited by this paper
• A Randomized Trial to Assess Anti-HIV Activity in Female Genital Tract Secretions and Soluble Mucosal Immunity Following Application of 1% Tenofovir Gel

  2011cited by this paper
• Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.

  2011influential reference
• Nano-NRTIs: Efficient Inhibitors of HIV Type-1 in Macrophages with a Reduced Mitochondrial Toxicity

  2010cited by this paper
• Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women

  2010cited by this paper
• The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards.

  2009cited by this paper
• BMC Infectious Diseases BioMed Central Research article Combination antiretroviral drugs in PLGA nanoparticle for HIV-1

  2009cited by this paper
• Changes in Mitochondrial Rna Production in Cells Treated with Nucleoside Analogues

  2005cited by this paper
• Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells

  2005cited by this paper
• Construction of Human‐SCID Chimeric Mice

  1998cited by this paper

• No citing papers are available for this paper.